| __timestamp | Amicus Therapeutics, Inc. | Sarepta Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 47624000 | 94231000 |
| Thursday, January 1, 2015 | 76943000 | 146394000 |
| Friday, January 1, 2016 | 104793000 | 188272000 |
| Sunday, January 1, 2017 | 149310000 | 166707000 |
| Monday, January 1, 2018 | 270902000 | 401843000 |
| Tuesday, January 1, 2019 | 286378000 | 560909000 |
| Wednesday, January 1, 2020 | 308443000 | 722343000 |
| Friday, January 1, 2021 | 272049000 | 771182000 |
| Saturday, January 1, 2022 | 276677000 | 877090000 |
| Sunday, January 1, 2023 | 152381000 | 877387000 |
Igniting the spark of knowledge
In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Sarepta Therapeutics, Inc. and Amicus Therapeutics, Inc. have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, Sarepta consistently outspent Amicus, with its R&D expenses peaking at nearly 880% higher than its 2014 levels by 2023. In contrast, Amicus saw a more modest increase, with its R&D spending growing by approximately 220% over the same period. This disparity highlights Sarepta's aggressive pursuit of innovation, particularly in the field of genetic medicine. Meanwhile, Amicus's steady investment reflects a more cautious approach, focusing on rare diseases. As the biotech landscape evolves, these spending patterns may offer insights into each company's strategic priorities and potential future breakthroughs.
Research and Development: Comparing Key Metrics for Eli Lilly and Company and Amicus Therapeutics, Inc.
Bristol-Myers Squibb Company vs Sarepta Therapeutics, Inc.: Strategic Focus on R&D Spending
Analyzing R&D Budgets: Zoetis Inc. vs Amicus Therapeutics, Inc.
Research and Development Expenses Breakdown: BioMarin Pharmaceutical Inc. vs Amicus Therapeutics, Inc.
Analyzing R&D Budgets: Sarepta Therapeutics, Inc. vs ImmunityBio, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Sarepta Therapeutics, Inc. and BioCryst Pharmaceuticals, Inc.
R&D Insights: How Exelixis, Inc. and Amicus Therapeutics, Inc. Allocate Funds
Comparing Innovation Spending: CymaBay Therapeutics, Inc. and Amicus Therapeutics, Inc.
Research and Development Investment: Apellis Pharmaceuticals, Inc. vs Amicus Therapeutics, Inc.
R&D Spending Showdown: Perrigo Company plc vs Amicus Therapeutics, Inc.
Research and Development Expenses Breakdown: Amicus Therapeutics, Inc. vs Geron Corporation
R&D Spending Showdown: Amicus Therapeutics, Inc. vs Galapagos NV